Price · as of 2024-12-31
$3.82
Market cap 111.61M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $30.94 | +709.95% |
| Intrinsic Value(DCF) | $1.37 | -64.14% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $80.67 | +2,011.83% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $0.00 | $27.95 | |||
| 2020 | $22.22 | $28.11 | $0.00 | $0.00 | $0.00 |
| 2021 | $4.60 | $275.84 | $11,243.82 | $0.00 | $0.00 |
| 2022 | $1.35 | $21.29 | $1.73 | $0.00 | $0.22 |
| 2023 | $2.82 | $43.04 | $3,153.25 | $0.00 | $0.00 |
| 2024 | $2.03 | $30.94 | $0.93 | $0.00 | $80.67 |
AI valuation
Our deep-learning model estimates Adagene Inc.'s (ADAG) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $30.94
- Current price
- $3.82
- AI upside
- +709.95%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.37
-64.14% upside
Graham-Dodd
—
— upside
Graham Formula
$80.67
+2,011.83% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ADAG | Adagene Inc. | $3.82 | 111.61M | +710% | -64% | — | +2,012% | -2.19 | 1.45 | 708.59 | -0.20 | -2.88 | 1.45 | -797.49% | -34835.42% | -32386.45% | -55.21% | 216.17% | -32.61% | 0.37 | -42.20 | 2.30 | 2.23 | 2.11 | 7593.00% | -9943.00% | 419.00% | -40.66% | -0.78 | 178.88% | 0.00% | 0.00% | 0.00% | -0.18 | -0.22 | 62.29 | -4.41 |
| ACET | Adicet Bio, Inc. | $7.25 | 69.44M | — | — | — | — | -0.60 | 0.37 | — | 0.81 | — | 0.37 | 0.00% | — | — | -65.65% | -433.12% | -54.79% | 0.09 | -31903.75 | 9.29 | 9.09 | 0.35 | -5982.00% | — | -477.00% | -133.68% | -4.76 | -317.32% | 0.00% | 0.00% | 0.00% | 0.70 | 0.95 | — | -2.95 |
| CRVO | CervoMed Inc. | $3.99 | 36.92M | — | — | — | — | -1.10 | 0.46 | — | 1.16 | -0.75 | 0.46 | 0.00% | — | — | -69.95% | 26851.40% | -61.41% | 0.00 | — | 11.11 | 10.61 | 0.49 | 14634.00% | — | 12189.00% | -92.65% | -4.26 | 24352.48% | 0.00% | 0.00% | 6.76% | 1.16 | 1.28 | — | 0.16 |
| FBIO | Fortress Biotech, Inc. | $3.42 | 106.15M | +410% | -82% | — | +1,342% | -0.26 | 1.41 | 0.55 | -0.49 | — | -3.51 | 63.80% | -191.38% | -79.75% | -533.80% | -308.14% | -77.53% | 3.34 | -11.12 | 1.27 | 0.95 | -0.18 | -6824.00% | -3176.00% | -3017.00% | -297.40% | -1.12 | -265.74% | 14.72% | -3.90% | 14.72% | -0.46 | -0.53 | 0.88 | -9.03 |
| GANX | Gain Therapeutics, Inc. | $2.61 | 100.39M | +1,143% | — | — | — | -2.11 | 5.86 | — | -1.64 | — | 5.97 | 0.00% | — | — | -204.95% | 729.11% | -132.83% | 0.09 | — | 2.97 | 2.85 | 0.48 | -4795.00% | -10000.00% | 8.00% | -43.93% | -4.83 | 677.01% | 0.00% | 0.00% | 0.00% | -1.64 | -1.76 | — | -8.76 |
| LITS | Lite Strategy, Inc. | $1.13 | 41.55M | +12,712% | — | — | — | -1.77 | 1.66 | — | -0.60 | — | 1.66 | 0.00% | — | — | -63.84% | 545.04% | -53.45% | 0.00 | — | 13.50 | 13.30 | 1.05 | -18951.00% | -10000.00% | -5871.00% | -73.96% | -15.39 | 650.87% | 0.00% | 0.00% | 50.76% | -0.58 | -0.49 | — | -20.49 |
| NRXP | NRx Pharmaceuticals, Inc. | $1.86 | 32.15M | — | — | — | — | -0.91 | -0.98 | — | -1.16 | — | -0.98 | 0.00% | — | — | 143.76% | 156.03% | -458.25% | -0.28 | -18.26 | 0.15 | 0.07 | -0.21 | -3995.00% | — | -5089.00% | -46.61% | -0.49 | 84.23% | 0.00% | 0.00% | 0.00% | -1.42 | -2.63 | — | -130.11 |
| NTRB | Nutriband Inc. | $4.44 | 54.06M | +340% | -57% | — | — | -4.78 | 7.79 | 23.39 | -4.51 | -10.98 | 11.26 | 32.68% | -312.62% | -489.86% | -162.94% | -157.60% | -139.89% | 0.03 | -312.51 | 4.88 | 4.46 | 0.41 | 4348.00% | 262.00% | 3184.00% | -9.43% | -4.71 | -111.17% | 0.00% | 0.00% | 8.03% | -6.87 | -9.73 | 21.47 | 19.59 |
| TCRX | TScan Therapeutics, Inc. | $1.06 | 60.15M | +2,649% | +18% | — | +7,924% | -1.74 | 0.92 | 78.74 | -0.24 | — | 0.92 | 100.00% | -4787.68% | -4527.66% | -65.08% | -271.01% | -39.64% | 0.40 | -36.91 | 8.14 | 8.07 | 0.68 | -1618.00% | -8662.00% | 7774.00% | -51.70% | -3.08 | -230.45% | 0.00% | 0.00% | 18.21% | -0.22 | -0.25 | 10.30 | -0.75 |
| XBIT | XBiotech Inc. | $2.26 | 68.9M | — | — | — | — | -2.57 | 0.54 | — | 1.76 | -4.62 | 0.54 | 0.00% | — | — | -19.21% | -219.51% | -18.10% | 0.06 | -52.63 | 11.56 | 11.49 | 4.51 | 5556.00% | — | 6905.00% | -32.59% | -2.05 | -166.91% | 0.00% | 0.00% | 0.00% | 1.49 | 1.97 | — | 3.15 |
About Adagene Inc.
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
- CEO
- Peter Luo
- Employees
- 138
- Beta
- 0.73
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.37 ÷ $3.82) − 1 = -64.14% (DCF, example).